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Abstract 
Objective: The incidence of immune-related adverse events is growing as the use of check-
point inhibitors is exponentially increasing. Cutaneous adverse events are among the most 
frequent immune-related adverse events. The purpose of this case report and literature review 
is to highlight psoriasis as a potential adverse event with need for early recognition. Case Re-
port and Literature Review: We describe the case of a 65-year-old woman with psoriasis 
exacerbation while treated with nivolumab (anti-PD-1) for a stage IV melanoma. She had a 
history of scalp psoriasis but she presented with psoriatic lesions on both lower and upper 
limbs. Our patient was treated with topical steroids. So far, 34 other cases with an exacerbation 
of psoriasis during treatment with anti-PDL-1 or PD-1 therapy have been reported in the liter-
ature. A broad range of therapies are described, without any available guidelines for this par-
ticular condition. Conclusion: Psoriasis exacerbation is an established side effect of PD-1/ 
PDL-1 checkpoint inhibitors with 35 reported cases. Early recognition and management are 
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challenging as there are no clear guidelines available. A close collaboration between oncologist 
and dermatologist is mandatory to manage this immune-related adverse event. 
 © 2018 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
The use of immune checkpoint inhibitors (ICI) is exponentially increasing as it has be-
come the standard of care for several cancer types. Currently, 2 types of ICI are used in the 
clinic: first, anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and second, anti-pro-
grammed cell death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) inhibitors. Inherent 
to the mechanism of action, immune-related adverse events (irAEs) are seen. Every organ is 
at risk, but skin toxicity is among the most frequent adverse events. Nonspecific maculopapu-
lar rash and pruritus represent the most common manifestations [1]. Other entities are less 
frequent and not so well documented. We present a case of psoriasis vulgaris exacerbation in 
a patient treated with nivolumab (anti-PD-1). The purpose of this paper is to point to the pos-
sibility of psoriasis vulgaris exacerbation as a potential irAE and to discuss the management 
of this adverse event.  
Case Presentation 
A 65-year-old woman presented with multiple itchy erythematosquamous plaques on 
both lower and upper limbs ongoing for 1 week. In addition, psoriasiform scales on the scalp 
and retroauricular were observed. Full-body inspection revealed no other skin lesions. The 
patient was in good general condition. She had no other complaints and felt generally well. 
She denied systemic complaints such as weight loss, night sweats, fever, dyspnea, cough, or 
gastrointestinal symptoms. The patient had been treated with nivolumab 3 mg/m2 (anti-PD-
1) every 2 weeks for a stage IV melanoma. At the time of presentation, the treatment had been 
administered 11 times. Two years ago, she was diagnosed with a stage IV melanoma, positive 
for the BRAF V600 mutation. She was diagnosed with lymph node, subcutaneous, and brain 
metastases. Nivolumab was initiated as a third-line treatment, after a BRAF enzyme inhibitor 
and ipilimumab (CTLA-4 inhibitor). Ipilimumab was stopped after 2 cycles because of grade 3 
diarrhea. Since the treatment with nivolumab, a disease stabilization was observed. The pa-
tient had a known history of scalp psoriasis, type II diabetes, and hypertension. Her regular 
medication included lorametazepam, gliclazide, metoprolol, pantoprazole, and momethasone 
nasal spray. 
Based on the clear clinical image, the patient was diagnosed with a psoriasis vulgaris ex-
acerbation. The clinical image is shown in Figure 1. No skin biopsy was obtained. Local treat-
ment with corticosteroids was initiated. Additionally, on patient request, the interval of 
nivolumab was extended from 2 weeks to 3 weeks, because she noticed a flare-up of the skin 
lesions after every nivolumab administration. Dosing at 3-week intervals, in combination with 
the local corticoid treatment, led to successful control of the psoriatic lesions. No systemic 
corticoids were administered. The patient had a stable disease for 14 months after the start of 
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nivolumab. Then, she developed progressive brain metastasis with an intracranial hemor-
rhage and died.  
Literature Review 
A bibliographic search was conducted on PubMed using the key words: “psoriasis” and 
“nivolumab,” “pembrolizumab,” “atezoluzimab,” “anti PD-1,” or “anti PDL-1.” Thirty-four cases 
with psoriasis linked to anti-PD-1 or anti-PDL-1 treatment were retained. An overview is 
given in Table 1 and Table 2. Twelve individual cases were described. Two authors published 
a collection of 17 and 5 cases, respectively, in 1 publication [2, 3]. Two additional publications 
also reported on psoriasis exacerbation but were not included in the tables because detailed 
information is missing [4, 5].  
Discussion 
We describe an exacerbation of a mild pre-existing psoriasis under anti-PD-1 therapy. An 
extension of the disease with new localizations was observed. We hypothesize that nivolumab 
was the trigger to the psoriasis exacerbation in our patient. However, we should mention that 
a psoriasis exacerbation can be triggered by multiple factors, such as stress and skin injury. In 
our case, the sequence of events and a clearly observed flare-up of the lesions after each anti-
PD-1 infusion suggest a causal link between the administration of nivolumab and the psoriasis 
exacerbation. Indeed, several cases of psoriasis exacerbation following PD-1 or PDL-1 inhibi-
tion have been reported. In Table 1 and Table 2, we describe 34 other cases. The majority of 
cases show a psoriasis flare in patients with pre-existing disease, but a new-onset disease has 
been reported in 5 cases. Apart from these case reports, 2 publications on adverse events of 
anti-PD-1 mention psoriasis exacerbation. Danlos et al. [4] report a psoriasis flare in 4 out of 
13 patients with psoriasis and Menzies et al. [5] report a flare in 3 out of 6 patients . The num-
ber of cases reported suggests that psoriasis exacerbation after ICI may be more common. 
However, reliable data on the prevalence and incidence of psoriasis in patients treated with 
anti-PD-1/PDL-1 antibodies are still lacking. In order to detect side effects at an early stage, it 
is recommended that these side effects of immunotherapy are searched for during each clini-
cal examination. Registration in a systematic way is needed to obtain reliable epidemiologic 
data. This might also have a predictive value as some retrospective data suggested a better 
outcome for patients with cutaneous irAEs [6, 7]. At this moment it is unclear whether this is 
true for psoriasis induced by ICI. 
A possible rationale for the pathogenesis can be given but remains speculative. Psoriasis 
is known as a T-cell- and dendritic-cell-mediated disease. IL-17 and IL-22 produced by T 
helper (Th) 1, 17, and 22 cells play an important role [8]. Th cells are downregulated by the 
PD-1 pathway. By inhibiting this pathway, an upregulation of Th-17 cells is observed [9]. Th-
17 upregulation might be the explanation why this patient had psoriasis exacerbation parallel 
to the anti-PD-1 infusion. 
The recognition of psoriasis induced by ICI is important for adequate management. Gen-
eral management for skin toxicity of ICI describes the use of topical emollients, antihistamines, 
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and corticoids [10]. For psoriasis, a more specific approach is needed. Prior recommendations 
for drug-induced psoriasis were to stop the causal drugs and start classic treatment options 
for psoriasis vulgaris. These treatment options are currently topical corticosteroids, vitamin 
D analogues, ultraviolet-based phototherapy, and systemic treatments, such as methotrexate, 
acitretin, and fumaric acid esters, and biologics [11]. Because of the underlying malignant con-
dition, cyclosporine and many of the novel biologic agents are preferably avoided in patients 
with PD-1/PDL-1-induced psoriasis unless other severe irAEs are present, e.g., ICI-induced 
colitis not responding to systemic corticotherapy [3]. Our patient was successfully treated 
with topical steroids and prolongation of the dosing interval of nivolumab. Indeed, some cases 
describe good results with topical treatment with corticoids and vitamin D analogues [12–15]. 
However, in several cases local treatment was insufficient with need for oral prednisolone [2, 
16, 17], acitretin (vitamin A derivate), or phototherapy [2, 16, 18, 19]. One patient with con-
comitant psoriasis arthritis was also treated with oral methotrexate [20]. In most cases, pso-
riatic lesions were controlled without the need to permanently discontinue the anti-PD-1/ 
PDL-1 therapy; often, only a short break is reported. If psoriasis exacerbation or de novo pso-
riasis is suspected, we suggest a rapid referral to a dermatologist to initiate a proper local and 
if needed systemic treatment. With proper treatment, a discontinuation of the ICI can be 
avoided in most cases. 
Conclusion 
Psoriasis exacerbation is an established side effect of PD-1/PDL-1 checkpoint inhibitors 
with 35 reported cases. Early recognition and management are challenging with no clear 
guidelines available. A close collaboration between oncologist and dermatologist is manda-
tory to manage this specific irAE.  
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Fig. 1. Psoriatic lesions on both lower and upper limbs. 
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Table 1. Overview of psoriasis exacerbations and de novo psoriasis in patients treated with anti-PD-1/anti-
PDL-1 therapy 
              
              
Patient age, 
years/ 
gender 
Cancer  
type 
 Treatment  
regimen 
 Time between 
start of PD-1/ 
PDL-1  
inhibitor and  
appearance  
of psoriasis 
Personal 
history of  
psoriasis 
 Psoriasis  
management 
 Discontinuation  
of PD-1/PDL-1  
inhibitor 
Tumor response  
to PD-1/PDL-1  
inhibitor 
 First author  
[Ref.], year 
              
              
80/M Primary oral 
mucosal 
melanoma 
 Nivolumab  
2 mg/kg every  
3 weeks 
 12 weeks No  Oral prednisolone,  
resulted in therapeutic 
effect 
 No 3 months after  
the last dose of 
nivolumab, the  
lesions on the  
palate decreased in 
size; no melanoma 
cells were found in 
a biopsy taken 
from the upper lip 
 Ohtsuka [17], 
2015 
                            65/M Metastatic 
oral mucosal 
melanoma 
 Nivolumab  
2 mg/kg every  
3 weeks, after 
subcutaneous 
interferon-β  
injections for  
5 days 
 3 weeks Yes  – Topical steroid 
(clobetasol propionate 
0.05%) and vitamin  
D3 analogue, without 
response 
– UVB therapy, without 
response 
– Oral etretinate 30 
mg/day, resulted in 
therapeutic effect 
 No NA  Kato [16], 
2015  
                            45/M Metastatic 
renal cell 
carcinoma 
 Nivolumab  
3 mg/kg every  
2 weeks 
 2 weeks No  Calcipotriol/ 
betamethasone gel,  
resulted in therapeutic 
effect 
 Yes;  
interruption  
of 21 days 
Partial response  
on CT scan 
 Ruiz- 
Bañobre 
[13], 2017 
                            87/M Metastatic 
cutaneous 
melanoma 
 Nivolumab  
2 mg/kg every  
3 weeks  
 6 weeks Yes  Systemic corticoids  
(0.5 mg/kg), resulted  
in therapeutic effect 
 Yes;  
interruption  
because of  
concomitant  
pneumonitis 
NA  Matsumura 
[9], 2015 
                            80/F Metastatic 
cutaneous 
melanoma 
 Pembrolizumab  Between 3  
and 6 weeks 
NA  Local corticoids  Yes Yes  Totonchy 
[15], 2016 
                            67/M Metastatic 
adenocarci-
noma of the 
lung 
 Pembrolizumab  3 weeks  Yes  Acitretin  Yes;  
interruption  
of 4 weeks 
NA  Sahuquillo-
Torralba 
[19], 2016 
                            NA NA  Pembrolizumab  9 weeks Yes  Topical and systemic 
corticoids 
 Yes;  
interruption  
of 1 week  
NA  Sanlorenzo 
[21], 2015 
              
              
NA, not applicable. 
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Table 2. Overview of psoriasis exacerbations and de novo psoriasis in patients treated with anti-PD-1/anti-
PDL-1 therapy (continued) 
              
              
Patient age, 
years/ 
gender 
Cancer  
type 
 Treatment  
regimen 
 Time between 
start of PD-1/ 
PDL-1  
inhibitor and  
appearance  
of psoriasis 
Personal  
history of  
psoriasis 
 Psoriasis  
management 
 Discontinuation  
of PD-1/PDL-1  
inhibitor 
Tumor response  
to PD-1/PDL-1  
inhibitor 
First author  
[Ref.], year 
              
              
17 patients: 
age 35–87 
years/ 
F/M 
Melanoma/ 
lung  
carcinoma 
 Pembrolizumab/ 
nivolumab 
 NA NA  Topical, systemic  
corticosteroids,  
acitretin,  
phototherapy  
 NA NA  Bonigen [2], 
2017 
                            67/M Advanced 
non-small 
cell lung  
cancer  
 Nivolumab  
3 mg/kg every  
3 weeks  
 3 weeks No  Topical corticoids,  
resulted in  
therapeutic effect   
 No NA  Yamamoto 
[14], 2018  
                            67/M Stage IV  
melanoma 
 Pembrolizumab  
2 mg/kg every 3 
weeks 
 15 weeks Yes  Acitretin and narrow  
band ultraviolet B  
phototherapy 
 Yes;  
interruption  
of 4 weeks 
Yes  Phadke  
[18], 2016 
                            5 patients: 
mean age  
66 years/ 
F/M 
3 NSCLC,  
1 papillary 
urothelial 
carcinoma,  
1 squamous 
cell  
carcinoma  
of the tonsil 
 3 patients treated 
with anti-PD-1 
therapy (1 with 
pembrolizumab,  
2 with nivolumab)  
2 patients treated 
with anti-PDL-1 
therapy  
(durvalumab) 
 Between 2 
weeks and  
2 months 
In 3 out of 5  
patients the  
personal  
history was  
positive for  
psoriasis  
 Topical steroids,  
ultraviolet B  
phototherapy,  
systemic steroids 
 In 1 out of 5  
patients therapy  
was interrupted 
NA  Voudouri [3], 
2017 
                            89/M Metastatic  
melanoma 
 Nivolumab  
3 mg/kg every  
2 weeks 
 2 weeks No  Calcipotriol/ 
betamethasone  
dipropionate (local)  
 No  No   Murata [12], 
2017 
                            80/M NSCLC  Nivolumab  
3 mg/kg every  
2 weeks 
 16 weeks No  Oral methotrexate  
at a dose of 10 mg/ 
week in combination  
with low-dose 15 mg  
oral prednisone/ 
day and topical  
corticosteroids 
 Yes;  
interruption  
of 4 weeks   
Yes  Law-Pingman 
[20], 2016 
                            65/F Metastatic  
melanoma 
 Nivolumab  
3 mg/kg every  
2 weeks 
 20 weeks Yes  Topical corticosteroids, 
prolongation of  
treatment interval  
to 3 weeks 
 Yes;  
nivolumab every  
3 weeks instead  
of every 2 weeks  
Yes  Our case  
              
              
NA, not applicable. 
 
 
 
 
 
